Sulin Shah

Founder & Legal Consultant / Fractional General Counsel

Serves as fractional General Counsel and compliance leader to multiple life sciences and healthcare clients. Guided a publicly traded rare disease company through headcount growth from 30 to 150+ employees, culminating in the successful launch of the first FDA-approved therapy for its target indication. Negotiated a $200M+ BARDA contract for a clinical-stage biotech developing government-funded medical countermeasures. Leads M&A execution and advises on corporate governance for a fast-growing veterinary care consolidator, including asset purchase agreements and acquisition integration.

Vice President, U.S. General Counsel

Chief legal counsel for the U.S. subsidiary of a Taiwan-based rare oncology biopharma, with the U.S. operations representing approximately 85% of global revenues. Supported FDA approval and successful commercial launch of BESREMi. Advised on initiatives driving a 100% year-over-year revenue increase post-launch and a 450% increase in parent company market capitalization. Counseled on a $462M global depository receipt offering and led an exclusive licensing transaction with a Latin America partner.

Vice President, U.S. General Counsel

Built the U.S. legal, compliance, and human resources functions for a Denmark-based rare disease pharmaceutical company, growing the U.S. team from 4 to 36 employees in 16 months. Led the company's U.S. Nasdaq dual listing and periodic securities filings. Established contracting frameworks, market access programs, and a U.S. compliance infrastructure. Played a key leadership role guiding the company through an FDA complete response letter, including restructuring efforts and resubmission strategy.

Lead Counsel, U.S. Hematology (Takeda/Shire) · Senior Counsel (Baxalta/Baxter)

Served as lead legal counsel for the U.S. Hematology franchise (>$1.8B annual revenue) through Baxalta's spin-off from Baxter, Shire's $32B acquisition of Baxalta, and Takeda's $62B acquisition of Shire — one of the largest pharma deals in history. Guided multiple product launches and held progressively senior roles across legal, compliance, and business development through three major corporate integrations. Recognized as a top performer throughout, earning Shire's highest performance rating for 2016, 2017, and 2018.

Associate, Health Law & M&A / Private Equity

Began career at one of the country's preeminent healthcare law firms, practicing in the Health Law and M&A/Private Equity groups. Represented private equity clients, large hospital systems, and publicly and privately held corporations on transactions, including acquisitions, divestitures, and joint ventures.